A new analysis of the global market for psychedelics performed by Brandessence Market Research shows an expected growth from 2022’s $4.87 billion to an annual valuation of nearly $12 billion before 2030.

According to the report, the market for psychedelic drugs used for therapeutic purposes -including LSD, ketamine, MDMA, psilocybin and ayahuasca- would expand at a Compound Annual Growth Rate (CAGR) of 13.49%. 

The analysis highlights what it considers to be the world’s key players in the industry, including a couple of businesses that have been specifically created for the purpose of developing psychedelics -see COMPASS Pathways (NASDAQ: …

Full story available on Benzinga.com